A RANDOMIZED TRIAL OF COGNITIVE BEHAVIOR THERAPY AND ARMODAFINIL TO TREAT INSOMNIA AND DAYTIME SLEEPINESS IN CANCER SURVIVORS

Sheila N. Garland, Holly Barilla, James Findley, Philip Gehrman, Michael Perlis

University of Pennsylvania

INTRODUCTION: Insomnia and fatigue are the most frequently reported side effects associated with cancer. Although cognitive behavioral therapy for insomnia (CBT-I) is effective in addressing difficulty initiating and maintaining sleep, it frequently results in (short-term) sleepiness and fatigue. This may make it difficult for cancer patients to adhere to treatment. This study examines whether a combination of CBT-I and a wake-promoting medication (armodafinil) results in greater overall improvement in insomnia and fatigue symptoms among cancer survivors.

METHODS: Eighty-eight patients were randomized to one of four treatment conditions: 1) CBT-I + placebo (CBT+P), 2) CBT-I + armodafinil (CBT+M), 3) Placebo only (P) and 4) armodafinil only (M). CBT-I was delivered in 7 weekly one-hour individual therapy sessions (3 in person, 4 via telephone). Pre-post findings on sleep diary-measured sleep latency (SL), wake after sleep onset (WASO), total sleep time (TST), and daytime sleepiness measured by the Epworth Sleepiness Scale (ESS), are reported.

RESULTS: The mean age of the group was 56yrs, 88% were female and the majority of patients (68%) had breast cancer. All analyses were adjusted for baseline severity. Compared to the placebo group, patients in the CBT+P and CBT+M groups reported a significant reduction in SL with effect sizes of 0.67 and 0.58, respectively. There was a significant reduction in WASO in the CBT+M group only (p=.02). TST increased in the M group, but not in the CBT+P or CBT+M groups. There were no statistically significant reductions in daytime sleepiness (ESS) observed for any of the groups.

CONCLUSION: CBT-I alone and in combination with armodafinil was able to produce statistically and clinically significant improvement in self-reported sleep. The addition of armodafinil did not appear to enhance the effect of CBT-I via a reduction in daytime sleepiness. Analyses are ongoing to examine the impact of armodafinil on CBT-I compliance.